homepage-top-section

According to the company, the new programme is based on data showing that ST266 significantly decreased the inflammatory response of a body in a range of diseases and

The latest deal is said to leverage an existing agreement between the two companies established in 2018 for the development of mRNA vaccines for infectious diseases. Translate Bio

Under the deal, Vir can non-exclusively access Xencor’s Xtend Fc technology to expand the half-life of novel antibodies, which are being assessed as potential treatments for patients with

The company is working with the US Food & Drug Administration (FDA) to commence a randomised, double-blind and placebo-controlled phase III clinical trial in collaboration with the Biomedical

Under material transfer and collaboration agreement, the companies will co-develop and supply potential mRNA-based coronavirus vaccine for the prevention of COVID-19 infection. The vaccine will not be supplied

The regulator has accepted the firm’s new drug application (NDA) for the accelerated approval of tazemetostat to treat patients with relapsed or refractory FL who have secured at

The gantenerumab arm of phase II/III DIAN-TU-001 study has failed to meet its primary endpoint in people who have an early-onset, inherited form of AD or otherwise known

The company has reported positive topline results from the pivotal part 2 of the FIREFISH study, which is assessing risdiplam in infants aged between one and seven months

DRG is engaged in offering high-value data, analytics and insights products and services to the healthcare industry. The deal includes $900m in cash, as well as issuing of